These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 32367191)
1. Vaccination against the Epstein-Barr virus. Rühl J; Leung CS; Münz C Cell Mol Life Sci; 2020 Nov; 77(21):4315-4324. PubMed ID: 32367191 [TBL] [Abstract][Full Text] [Related]
2. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688 [TBL] [Abstract][Full Text] [Related]
3. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Cui X; Snapper CM Front Immunol; 2021; 12():734471. PubMed ID: 34691042 [TBL] [Abstract][Full Text] [Related]
4. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413 [No Abstract] [Full Text] [Related]
5. Vaccine Development for Epstein-Barr Virus. Cohen JI Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681 [TBL] [Abstract][Full Text] [Related]
6. Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature. Winter JR; Jackson C; Lewis JE; Taylor GS; Thomas OG; Stagg HR J Glob Health; 2020 Jun; 10(1):010404. PubMed ID: 32257152 [TBL] [Abstract][Full Text] [Related]
7. The Development of Prophylactic and Therapeutic EBV Vaccines. Smith C; Khanna R Curr Top Microbiol Immunol; 2015; 391():455-73. PubMed ID: 26428385 [TBL] [Abstract][Full Text] [Related]
8. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model. Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y Front Immunol; 2018; 9():932. PubMed ID: 29765376 [TBL] [Abstract][Full Text] [Related]
9. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma. Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566 [TBL] [Abstract][Full Text] [Related]
10. Epstein Barr virus - a tumor virus that needs cytotoxic lymphocytes to persist asymptomatically. Münz C Curr Opin Virol; 2016 Oct; 20():34-39. PubMed ID: 27591678 [TBL] [Abstract][Full Text] [Related]
11. The potential of currently unavailable herpes virus vaccines. Rajčáni J; Bánáti F; Szenthe K; Szathmary S Expert Rev Vaccines; 2018 Mar; 17(3):239-248. PubMed ID: 29313728 [TBL] [Abstract][Full Text] [Related]
15. GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection. Liu C; Li S; Qiao M; Zeng C; Liu X; Tang Y Arch Virol; 2024 Jul; 169(8):167. PubMed ID: 39020055 [TBL] [Abstract][Full Text] [Related]
16. Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus. Edwards KR; Schmidt K; Homad LJ; Kher GM; Xu G; Rodrigues KA; Ben-Akiva E; Abbott J; Prlic M; Newell EW; De Rosa SC; Irvine DJ; Pancera M; McGuire AT Cell Rep Med; 2024 Jun; 5(6):101587. PubMed ID: 38781964 [TBL] [Abstract][Full Text] [Related]
17. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses. Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082 [TBL] [Abstract][Full Text] [Related]